APYX - Apyx Medical gets FDA nod for Renuvion's use in improving loose skin on neck chin

• Apyx Medical ( NASDAQ: APYX ) said the U.S. Food and Drug Administration (FDA) granted 510(k) clearance to its Renuvion APR Handpiece for certain skin contraction procedures.
• The company noted that specifically, Renuvion is now indicated for use in subcutaneous dermatological and aesthetic procedures to improve the appearance of lax (loose) skin in the neck and submental region.
• "Building on this important achievement, we expect to commence a limited launch of Renuvion for this indication by the end of the third quarter of 2022, with the goal of entering full commercialization by the end of 2022," said Apyx ( APYX ) President and CEO Charlie Goodwin.
• APYX +2.93% to $7.72 premarket July 18

For further details see: